Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 11:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1609–1632 of 5,060 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Capsule 2 Clear all

Conditions: Healthy Volunteers
Interventions: Period 1 - Treatment Sequence AB, Period 1 - Treatment Sequence AC, Period 2 - Treatment Sequence AB, Period 2 - Treatment Sequence AC; Drug
Lead sponsor: Theriva Biologics, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Sleep, Pain, Depression, Anxiety
Interventions: Placebo Control Form 1 Capsules, Health Active Study Product 1.1 Capsules, Health Active Study Product 1.2 Capsules, Health Active Study Product 1.3 Capsules; Dietary Supplement
Lead sponsor: Radicle Science; Industry
Eligibility: 21 Years to 105 Years
Enrollment: 1,494 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Del Mar, California

Conditions: Chronic Genotype 1a or 1b HCV Infection
Interventions: GS-5885 tablet, GS-9451 tablet, tegobuvir capsule, ribavirin tablet, placebo matching ribavirin tablet, placebo matching tegobuvir capsule; Drug · Device
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 36
States / cities: Beverly Hills, California • Coronado, California • La Jolla, California + 28 more

Conditions: Multiple Myeloma, Myeloma Multiple, Kahler Disease, Myeloma, Plasma Cell, Myeloma-Multiple, Myelomatosis, Plasma Cell Myeloma
Interventions: Selinexor, Dexamethasone Oral, Daratumumab, Lenalidomide; Drug
Lead sponsor: US Oncology Research; Industry
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 10
States / cities: Tucson, Arizona • Denver, Colorado • Columbia, Maryland + 7 more

Conditions: Healthy Volunteers
Interventions: RO7017773 Phase I Capsule, RO7017773 Phase II Tablet Unflavored, RO7017773 Phase II Tablet Sweetened/Flavored; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Healthy Subjects
Interventions: PF-06651600, midazolam, efavirenz; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Type 2 Diabetes Mellitus
Interventions: Pioglitazone, Placebo, Pancreatic Clamp Study; Drug · Procedure
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2011
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Advanced Cancer
Interventions: Valproic Acid, Bevacizumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hepatitis C, Chronic
Interventions: BI 201335, Pegylated Interferon-alpha (IFN), Ribavirin (RBV), Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 678 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 18
States / cities: North Little Rock, Arkansas • Englewood, Colorado • Palm Harbor, Florida + 14 more

Conditions: Hypertension (HTN), Hypertension
Interventions: Arugula Extract, Psyllium Husk; Dietary Supplement
Lead sponsor: Baylor University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Waco, Texas

Conditions: Lymphoma, Infection, Leukemia
Interventions: Fluconazole, Voriconazole; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 2 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 33
States / cities: Birmingham, Alabama • La Jolla, California • Stanford, California + 25 more

Conditions: Hyperlipidemia
Interventions: Placebo, MBX-8025, Atorvastatin; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Huntington Beach, California + 24 more

Conditions: Multiple Sclerosis
Interventions: L-Histidine, Placebo, Lodosyn; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 60 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Diabetes Mellitus, Type 2
Interventions: BMS-512148, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 5
States / cities: Fort Lauderdale, Florida • Miami, Florida • Orlando, Florida + 2 more

Conditions: Autism
Interventions: docosahexaenoic acid (DHA), Placebo; Dietary Supplement
Lead sponsor: Mayo Clinic; Other
Eligibility: 3 Years to 10 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Crohn Disease
Interventions: infliximab infusion; AZA placebo caps, infliximab (IFX) infusion; azathioprine (AZA) caps, infliximab (IFX) placebo infusion; azathioprine (AZA) caps; Biological · Other · Drug
Lead sponsor: Centocor Ortho Biotech Services, L.L.C.; Industry
Eligibility: 21 Years to 99 Years
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 51
States / cities: Birmingham, Alabama • Phoenix, Arizona • Orange, California + 48 more

Conditions: 1. Endothelial Dysfunction (EndoPAT Score <=2)
Interventions: Chardonnay Seed Flour (CSF), Placebo; Dietary Supplement
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy
Interventions: Cefdinir Capsules 300 mg, OMNICEF® Capsule 300 mg; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 2
States / cities: East Grand Forks, Minnesota • Fargo, North Dakota

Conditions: Healthy Participants Study
Interventions: ALZ-507, Placebo; Drug
Lead sponsor: Alzheon Inc.; Industry
Eligibility: 50 Years to 75 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Cancer
Interventions: XS003 under fed and fasted condition; Drug
Lead sponsor: Xspray Pharma AB; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Medication Adherence
Interventions: ID Capsule, Riboflavin, Prompts; Other · Dietary Supplement · Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Diabetes Mellitus, Type II, Diabetes Mellitus, Non Insulin Dependent
Interventions: Canagliflozin (JNJ-28431754), Sitagliptin, Placebo; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 451 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 30
States / cities: Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 27 more

Conditions: Short Term Treatment of Insomnia
Interventions: Zaleplon; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetic Peripheral Neuropathy
Interventions: Suzetrigine, Pregabalin, Placebo (matched to SUZ), Placebo (matched to pregabalin); Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 194 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 50
States / cities: Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 47 more

Search by objective public record fields.

A Study to Evaluate the Effect of SYN-004 on the PK of IV Ceftriaxone in Adults With a Functioning Ileostomy

Radicle Health1: A Study of Health and Wellness Formulations and Their Effects on Overall Health

GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

A 2 Part Study to Assess the Relative Bioavailability of Tablet Formulation Compared to Capsule Formulation and the Effect of Food and Taste Assessment on the Tablet Formulation in Healthy Participants

ESTIMATION OF THE EFFECT OF MULTIPLE DOSE PF-06651600 ON THE PHARMACOKINETICS OF SINGLE DOSE MIDAZOLAM AND EFAVIRENZ

The Role of Acute Combined PPAR Alpha and Gamma Stimulation on Insulin Action in Humans

Valproic Acid and Bevacizumab in Patients With Advanced Cancer

Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-Experienced Genotype 1 Hepatitis C Infected Patients (STARTverso 3)

Under Pressure: Arugula Extract's Effect on Blood Pressure in Hypertensive Individuals

Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101)

Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol

Histaminergic Basis of Fatigue in Multiple Sclerosis

A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects

Docosahexaenoic Acid in the Treatment of Autism

Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC

Effects of Chardonnay Seed Flour on Vascular Health

Cefdinir Capsules 300 mg, Non-fasting

Safety and Pharmacokinetics of ALZ-507 in Healthy Elderly Adults

Bioavailability Study of XS003 (Nilotinib)

Smart Capsule for Automatic Adherence Monitoring

An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes

Bioequivalency Study of Zaleplon 10 mg Capsules Under Fed Conditions

Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)